| Literature DB >> 32936695 |
Allison M Gustavson1, Adam J Gordon2,3, Marie E Kenny1, Haley McHenry4, Julie Gronek5, Princess E Ackland1,6, Hildi J Hagedorn1,7.
Abstract
The actions needed to mitigate the spread of the coronavirus 2019 (COVID-19) have forged rapid paradigm shifts across healthcare delivery. In a time of crisis, continued access to and delivery of medication for opioid use disorder (M-OUD) is essential to save lives. However, prior to COVID-19, large variability in M-OUD adoption existed across the Veteran Health Administration (VHA) and it is unknown whether the COVID-19 pandemic exacerbated this divide. For the past two years, our team worked with eight VHA facilities to enhance adoption of M-OUD through a multi-component implementation intervention. This commentary explores these providers' responses to COVID-19 and the subsequent impact on their progress toward increasing adoption of M-OUD. Briefly, the loosening of regulatory restrictions fostered accelerated adoption of M-OUD, rapid support for telehealth offered a mechanism to increase M-OUD access, and reevaluation of current practices surrounding M-OUD strengthened adoption. Overall, during the COVID-19 crisis, facilities and providers responded positively to the call for increased access to M-OUD and appropriate care of patients with OUD. The VHA providers' responses and continued progress in enhancing M-OUD amidst a crisis may, in part, be attributable to their participation in an implementation effort prior to COVID-19 that established resources, expert support, and a community of practice. We anticipate the themes presented are generalizable to other healthcare systems grappling to deliver care to patients with OUD during a crisis. We propose areas of future research and quality improvement to continue to provide access and high quality, life-saving care to patients with OUD.Entities:
Keywords: COVID-19; coronavirus; implementation; medication for opioid use disorder; opioid use disorder
Mesh:
Substances:
Year: 2020 PMID: 32936695 PMCID: PMC8667808 DOI: 10.1080/08897077.2020.1809609
Source DB: PubMed Journal: Subst Abus ISSN: 0889-7077 Impact factor: 3.716